---

BIOASSAY - Viva Questions & Answers for MD Pharmacology

---

SECTION 1: DEFINITION AND FUNDAMENTALS

---

---

---

• The test and standard preparations must have the same pharmacological mode of action
• The active principle should produce the same measured response across all animal species used
• The dose-response curves (DRC) of the standard and test must be parallel (graded assays), so a potency ratio can be calculated
• The method must be reliable, sensitive, specific, and reproducible
• Individual biological variation must be minimized or accounted for
• The measured response must be the biological activity of interest

---

1. When the active principle has pharmacological activity but its chemical structure is unknown (e.g., long-acting thyroid stimulants - LATS)
2. When the active substance cannot be isolated or purified by chemical means
3. When chemical assays are unavailable or inadequate
4. When a mixture of substances with the same pharmacological action needs to be assayed as a whole (e.g., digitalis)
5. When biological activity of a drug must be standardized (e.g., insulin, heparin, oxytocin, ergot alkaloids, tubocurarine)
6. For quality control of biological products (vaccines, sera, antitoxins)
7. When physicochemical analysis is technically not feasible

---

• Highly sensitive and specific
• Measures actual pharmacological activity
• Simple and fast procedure for certain assays
• Possible with small volumes of test solution
• Only method when chemical structure is unknown

• Loss of tissue sensitivity (tachyphylaxis)
• Biological and methodological errors
• Time-consuming
• Dose-ranging studies are not always feasible
• Inter-animal variation

---

SECTION 2: TYPES OF BIOASSAY

---

1. Quantal (Direct Endpoint) Assay - "all or none" response
2. Graded (Quantitative) Assay - response proportional to dose

1. Matching / Direct matching (Bracketing) method
2. Interpolation method
3. Multiple point assays:
   • Three-point assay
   • Four-point assay (most common)
   • Six-point assay
4. Cumulative dose-response method

1. In vivo assays - intact animals
2. In vitro assays - isolated tissues/organ bath

---

• The drug produces an "all or none" response - the animal either shows the full response or does not respond at all
• The threshold dose (minimum dose producing a predetermined defined response) is measured for both standard and test preparation
• The potency ratio = threshold dose of standard / threshold dose of test
• Uses different animals for different doses

• Digitalis bioassay in cats (cardiac arrest as endpoint) - cat is anaesthetized with chloralose, drug infused slowly; the volume infused when the heart stops and BP falls to zero is the lethal dose
• Digitalis in guinea pigs (cardiac arrest)
• Insulin bioassay (hypoglycemic convulsions in mice)
• Ergot alkaloids (gangrenous changes)

• Drug effects appear rapidly and are easily recognized
• Drug effect is directly proportional to dose
• Rapid endpoint detection

---

• A graded response method
• The dose of the test preparation is adjusted to produce a response that matches (equals) the response of a given dose of the standard
• The test dose is "bracketed" between two doses of the standard (one producing a slightly smaller and one producing a slightly larger response)
• Potency ratio = dose of standard / dose of test that produces matching response
• Simple but requires careful technique
• Example: Matching method for oxytocin on isolated rat uterus

---

• A dose-response curve (DRC) of the standard is plotted first
• A single (or few) responses of the test preparation are obtained
• The unknown concentration is interpolated from the standard DRC
• Assumes the shape of the DRC is the same for test and standard
• More accurate than matching; used when only small amounts of test preparation are available

---

• Two doses of the standard (S1 and S2) and two doses of the test (T1 and T2) are compared
• The doses chosen are on the linear part of the log dose-response curve
• The ratio S1:S2 = T1:T2 (equally spaced on log scale)
• The DRCs for standard and test must be parallel
• Potency ratio is calculated by comparing the equieffective doses

• Provides a check on parallelism of DRCs (validity of the assay)
• More precise and statistically reliable than two-point or matching methods
• Allows calculation of confidence limits
• Standard method recommended by pharmacopoeias

---

SECTION 3: ORGAN BATH AND ISOLATED TISSUE PREPARATION

---

1. Organ bath chamber - glass vessel containing physiological salt solution (PSS) at the appropriate temperature; typically 10-50 mL capacity
2. Kymograph / recording drum - records tissue response; standard speed = 1 revolution/96 minutes (0.014 rpm); slow-contracting tissues use low speed, fast-contracting use higher speed; glossy side faces outward
3. Sherrington recording drum
4. Lever - Type 1 lever used in in vitro bioassays; must be lightweight, fine, and rigid to avoid bending; has a stylus (writing point)
5. Aerator - bubbles carbogen (95% O₂ + 5% CO₂) or oxygen through the bath
6. Water jacket - maintains constant temperature

• Mx = Distance (fulcrum to writing point) / Distance (fulcrum to tissue attachment) = A/B
• Slow-contracting tissue → high magnification (10-15×)
• Fast-contracting tissue → low magnification (5-10×)

---

• Provides ionic supply (Na⁺, K⁺, Ca²⁺, Mg²⁺, Cl⁻, HCO₃⁻, HPO₄²⁻)
• Provides nutritional supply (glucose as energy source)
• Maintains osmotic pressure
• Maintains pH (buffering)
• Prepared in distilled or deionized water

---

• Allow adequate dose cycle time: 3 minutes for fast-contracting tissues, 5 minutes for slow-contracting tissues
• Perform at least two tissue washes between doses
• Use lower concentrations where possible
• Avoid drugs known to cause tachyphylaxis (e.g., histamine, 5-HT) or account for it in the design

---

• Dose cycle: The time gap between successive drug additions to the organ bath
  • Fast-contracting tissues: 3 minutes
  • Slow-contracting tissues: 5 minutes
  • Must include at least 2 tissue washes
• Contact time: The duration for which the tissue is in contact with the drug before washing out

---

---

SECTION 4: SPECIFIC BIOASSAY EXAMPLES

---

• Type: Quantal (endpoint) assay
• Animal: Mice (male or female, uniform weight)
• Endpoint: Hypoglycemic convulsions (or loss of righting reflex)
• Method: Groups of fasted mice receive graded doses of standard and test insulin SC; the dose causing convulsions in 50% of animals is the ED50; potency ratio = ED50 standard / ED50 test
• Unit: International Unit (IU) - defined relative to WHO International Standard
• Historical note: First standardized using the mouse convulsion method

---

• Type: Quantal (direct endpoint) assay
• Animal: Cat (anaesthetized with urethane or chloralose) - classic method
• Endpoint: Cardiac arrest (cessation of heartbeat with fall of BP to zero)
• Method: Cat is anaesthetized and blood pressure is recorded; digitalis preparation is slowly infused IV; the dose at which cardiac arrest occurs is the lethal dose; compared with standard
• Alternative: Guinea pig cardiac arrest method
• Significance: Digitalis glycosides have a narrow therapeutic index and cannot be reliably quantified chemically since biological activity varies by preparation

---

• Type: Graded assay (matching/bracketing method)
• Tissue: Isolated rat uterus (estrogen-primed) in organ bath containing De-Jalon solution at 32°C
• Response measured: Uterine contraction (amplitude and frequency)
• Method: Standard and test oxytocin doses are compared; the dose of test that matches the response of the standard is determined
• Unit: International Unit - defined by WHO International Standard

---

• Type: Graded assay
• Tissue: Guinea pig ileum in Tyrode solution at 37°C
• Response: Contraction of ileum (histamine causes contraction of intestinal smooth muscle)
• Reference: Katzung's Basic and Clinical Pharmacology notes that "histamine-induced contraction of guinea pig ileum is a standard bioassay for this amine"
• Potency estimated by comparison with standard histamine

---

• Type: Graded assay (in vivo or in vitro)
• Tissue (in vitro): Frog rectus abdominis muscle
• Response: Neuromuscular blockade (inhibition of ACh-induced contraction)
• In vivo method: Cat head-drop method - dose that causes a specified degree of head drop in an anaesthetized cat
• Tubocurarine causes competitive neuromuscular blockade; its potency is compared with standard

---

SECTION 5: STATISTICAL AND TECHNICAL ASPECTS

---

• Potency ratio > 1: test preparation is more potent than standard
• Potency ratio < 1: test preparation is less potent than standard
• Potency ratio = 1: equal potency

---

• For a valid graded bioassay, the log dose-response curves (LDRCs) of the standard and test preparation must be parallel
• Parallelism confirms that the two preparations have the same mode of action and the only difference is potency
• Non-parallel curves indicate either different mechanisms of action or an invalid assay
• In a four-point assay, parallelism is tested by comparing the slopes of the two lines
• If lines are not parallel, the potency ratio cannot be validly calculated

---

• Inter-animal / inter-tissue variation (genetic, age, sex differences)
• Tachyphylaxis (rapid loss of tissue sensitivity)
• Tissue fatigue
• Disease in animals

• Inaccurate preparation of solutions (dilution errors)
• Temperature variation of bath
• Inadequate aeration of PSS
• Improper lever magnification
• Wrong kymograph speed
• Contamination of solutions

• Small sample size
• Inadequate randomization
• Failure to test for parallelism

---

1. Use a crossover design - same animal/tissue receives both standard and test
2. Use randomization of treatment allocation
3. Use homogeneous groups of animals (same species, strain, age, sex, weight)
4. Use Latin square design or randomized block design for multiple treatments
5. Use the four-point (or higher) assay design - allows statistical testing
6. Use sufficient replications
7. Appropriate wash-out periods between doses

---

• The WHO International Standard (or International Reference Preparation) is the primary reference material for biological standardization
• The International Unit (IU) is defined as the specific biological activity contained in a defined amount of the International Standard
• For example: 1 IU of insulin is the activity of 0.0347 mg of the WHO International Standard for insulin
• National standards are calibrated against the WHO standard
• This ensures that potency estimates from different laboratories worldwide are comparable

---

SECTION 6: MODERN PERSPECTIVES

---

• Imprecision: High inherent biological variability
• Slow: Time-consuming setup and execution
• Labor intensive: Requires skilled personnel and animal facilities
• Ethical concerns: Use of live animals (3Rs principle - Replace, Reduce, Refine)
• Tachyphylaxis: Limits number of assays per tissue
• Not specific enough for complex biological matrices
• Immunoassays (RIA, ELISA) offer superior sensitivity, precision, throughput, and avoid animal use - Tietz Textbook of Laboratory Medicine notes that "Bioassays tend to be imprecise and are now rarely used in clinical medicine"

---

1. Standardization of biological products where no chemical method exists (e.g., certain vaccines, botulinum toxin - mouse lethality bioassay remains the gold standard for BoNT, though alternatives like Endopep-MS are emerging)
2. Quality control of insulin, heparin, oxytocin, streptokinase batches by regulatory bodies
3. Research purposes - receptor characterization, pharmacological profiling
4. Detection of functional antibodies (e.g., thyroid-stimulating immunoglobulins - TSI requires a cell-based bioassay where patient serum is added to thyroid follicular cells; Henry's Clinical Diagnosis confirms this as the classic method for TSI)
5. Toxicology - evaluation of safety of chemicals, pesticides, environmental pollutants
6. Factor level assays in coagulation (bioassay measures ability of test plasma to normalize substrate-deficient plasma)

---

• Tietz notes that in vitro bioassays often "measure responses proximal or distal to a second messenger such as stimulation of cAMP formation"

---

• Three-point assay: One dose of standard + two doses of test (or two doses of standard + one dose of test); less precise than four-point
• Four-point assay: Two doses of standard (S1, S2) + two doses of test (T1, T2) - the preferred method; allows testing of parallelism and provides a valid statistical estimate of potency with confidence limits
• Six-point assay: Three doses each of standard and test - most precise, used for pharmacopoeial assays requiring high accuracy

---

• LD50: The dose of a drug that is lethal to 50% of animals in a given population under defined conditions. Determined by the quantal bioassay method.
• ED50: The dose that produces a specified (usually 50%) effect in 50% of the test population. Used in quantal bioassays.
• Therapeutic index (TI): TI = LD50 / ED50. A measure of drug safety - a higher TI indicates a wider margin of safety. (Note: clinically, TI is better measured as TI = TD50/ED50 using toxic rather than lethal dose.)

---

QUICK RECALL LIST: Key Drug-Tissue-PSS Combinations

---